Details of the Active Pharmaceutical Ingredient (API)

General Information of API (ID: D00834)
Name
Aminoglutethimide
Synonyms    Click to Show/Hide the Synonyms of This API
aminoglutethimide; 125-84-8; dl-Aminoglutethimide; Cytadren; Orimeten; p-Aminoglutethimide; Elipten; 3-(4-aminophenyl)-3-ethylpiperidine-2,6-dione; 3-(4-Aminophenyl)-3-ethyl-2,6-piperidinedione; 2,6-Piperidinedione, 3-(4-aminophenyl)-3-ethyl-; Aminoglutetimida; Aminoglutethimidum; 2-(p-Aminophenyl)-2-ethylglutarimide; Ba-16038; 3-Ethyl-3-(p-aminophenyl)-2,6-dioxopiperidine; (+/-)-p-AMINOGLUTETHIMIDE; Glutethimide, para-amino; Glutarimide, 2-(p-aminophenyl)-2-ethyl-; AG-1; 3-(4-aminophenyl)-3-ethyl-piperidine-2,6-dione; CHEMBL488; CHEBI:2654; alpha-(p-Aminophenyl)-alpha-ethylglutarimide; MFCD00010122; NSC-330915; DSSTox_CID_2589; DSSTox_RID_76647; .alpha.-(p-Aminophenyl)-.alpha.-ethylglutarimide; DSSTox_GSID_22589; (RS)-2-(4-Amino-phenyl)-2-ethyl-glutarimide;(RS)-3-(4-Amino-phenyl)-3-ethyl-2,6-dioxo-piperidine; Aminoglutethimidum [INN-Latin]; Aminoglutetimida [INN-Spanish]; Aminoglutetimide; Ba 16038; Cytadren (TN); SMR000326785; C 16038-BA; CCRIS 7562; aminoglutethimide (AG); SR-01000075596; 3-(4-Aminophenyl)-3-ethyl-2,6-piperidindion; EINECS 204-756-4; BRN 0210656; Aminoglutethimide (USP/INN); HSDB 7494; 3-(p-Aminophenyl)-3-ethylpiperidine-2,6-dione; Aminoglutethimide [USP:INN:BAN]; NCGC00016379-01; CAS-125-84-8; Prestwick_243; Spectrum_000040; (y)-p-Aminoglutethimide; Aminoglutethimide AG, 4; (?)-p-Aminoglutethimide; Prestwick0_000244; Prestwick1_000244; Prestwick2_000244; Prestwick3_000244; Spectrum2_000093; Spectrum3_000296; Spectrum4_000144; Spectrum5_000802; A 9657; SCHEMBL4306; Aminoglutethimide (Cytadren); Lopac0_000124; BSPBio_000028; BSPBio_001832; KBioGR_000588; KBioSS_000400; (A+/-)-p-Aminoglutethimide; MLS000859924; MLS001213216; DivK1c_000884; SPECTRUM1500115; SPBio_000046; SPBio_002247; BDBM9460; BPBio1_000032; GTPL7054; DTXSID8022589; HMS502M06; KBio1_000884; KBio2_000400; KBio2_002968; KBio2_005536; KBio3_001332; NINDS_000884; HMS1568B10; HMS1920C09; HMS2090I05; HMS2091I09; HMS2095B10; HMS2231M19; HMS3259H10; HMS3260I10; HMS3372M07; HMS3655O17; HMS3712B10; Pharmakon1600-01500115; 55511-44-9; 57288-03-6; AMY33415; BCP28501; EBD40055; HY-B0237; 2, 3-(4-aminophenyl)-3-ethyl-; Tox21_110406; Tox21_303497; Tox21_500124; BBL010961; CCG-38911; NSC330915; NSC755868; SBB000711; STK802074; 2-(4-aminophenyl)-2-ethylglutarimide; AKOS004120070; AKOS022060651; Tox21_110406_1; AT-2947; DB00357; LP00124; MCULE-9118268281; NC00714; NSC-755868; SDCCGSBI-0050112.P005; IDI1_000884; SMP1_000017; NCGC00015110-02; NCGC00015110-03; NCGC00015110-04; NCGC00015110-05; NCGC00015110-06; NCGC00015110-07; NCGC00015110-09; NCGC00015110-12; NCGC00015110-21; NCGC00093615-01; NCGC00093615-02; NCGC00093615-03; NCGC00093615-04; NCGC00093615-05; NCGC00257263-01; NCGC00260809-01; AC-12456; AS-13282; H801; NCI60_002900; SBI-0050112.P004; AB0013271; DB-021640; DB-072002; DB-072275; 3-Carboxy-1,1-dimethyl-, (E)-2-propenyl; AB00051935; EU-0100124; FT-0773944; S1672; SW196550-3; ( inverted question mark)-p-Aminoglutethimide; EN300-53368; VU0243029-3; C07617; D00574; K-1913; AB00051935-09; AB00051935-11; AB00051935_12; AB00051935_13; 125A848; A805433; Q241150; 3-(4-aminophenyl)-3-ethylazaperhydroine-2,6-dione; SR-01000075596-1; SR-01000075596-4; SR-01000075596-6; W-108399; BRD-A25234499-001-05-0; BRD-A25234499-001-09-2; Z1259341083; Aminoglutethimide, European Pharmacopoeia (EP) Reference Standard; Aminoglutethimide, United States Pharmacopeia (USP) Reference Standard
Clinical Status
Approved
PubChem CID
2145
Formula
C13H16N2O2
Canonical SMILES
CCC1(CCC(=O)NC1=O)C2=CC=C(C=C2)N
InChI
1S/C13H16N2O2/c1-2-13(8-7-11(16)15-12(13)17)9-3-5-10(14)6-4-9/h3-6H,2,7-8,14H2,1H3,(H,15,16,17)
InChIKey
ROBVIMPUHSLWNV-UHFFFAOYSA-N
   Click to Show/Hide the Molecular Data (Structure/Property) of This API
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=2145"></iframe>
3D MOL 2D MOL
Physicochemical Properties Molecular Weight 232.28 Topological Polar Surface Area 72.2
XlogP 1.2 Complexity 321
Heavy Atom Count 17 Rotatable Bond Count 2
Hydrogen Bond Donor Count 2 Hydrogen Bond Acceptor Count 3
Full List of Drug Formulations (DFMs) Containing This API
          Aminoglutethimide 250mg tablet Click to Show/Hide the Full List of Formulation(s):          1 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Cellulose Compounds; Colloidal Silicon Dioxide; Starch; Stearic Acid; Talc
                   Dosage Form Tablet
                   Company Novartis Pharmaceuticals Corp
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Stearic acid DIG Info Phosphodiesterase 3A (IC50 = 3.1 uM) [1]
Pregelatinized starch DIG Info Multidrug resistance protein 1 (Protein expression downregulation) [2]
References
1 The activities of drug inactive ingredients on biological targets. Science. 2020 Jul 24;369(6502):403-413.
2 Effects of commonly used excipients on the expression of CYP3A4 in colon and liver cells. Pharm Res. 2010 Aug;27(8):1703-12.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.